Kailera Therapeutics, Inc.
NASDAQ:KLRABiotechnology
+$0.51 today
- Market cap
- $1.53B
- Beta
- 0.00
Volume 0.42M
Average 0.80M
KLRA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Kailera Therapeutics, Inc.NASDAQ: KLRA
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA of -$111.31M in Q2 FY2026
Q2 FY2026 EBITDA was -$111.31M.
What to watch
Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$111.31M-31.6% QoQ
- Last fiscal yearDec 2025
- -$158.03M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | — | +100.0% | — |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (158.03M) USD
- Year-over-year change
- —
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (158.03M) | — |
EBITDA vs competitors
How KLRA compares with its peers on the latest reported figures
- KLRA's FY2025 EBITDA of -$158.03M is the 8th highest of the 10 companies compared; the peer median is -$89.21M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $78.84M | +1391.3% | — | — | |
| LTM Mar 2026 | -$715K | +96.9% | — | 1.9% | |
| LTM Mar 2026 | -$46.12M | +63.6% | — | — | |
| LTM Mar 2026 | -$88.27M | +2.7% | — | 245200.0% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -$89.21M | -28.4% | — | 864.8% |
| LTM Mar 2026 | -$106.88M | -21.2% | — | — | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | -$148.59M | -85.2% | — | — |
KLRAKailera Therapeutics, Inc. | FY2025 | -$158.03M | — | — | — |
| LTM Jun 2026 | -$254.91M | -32.5% | — | 3579.7% | |
| LTM Jun 2026 | -$534.34M | -212.4% | — | — | |
| Peer median (excluding KLRA) | -$89.21M | -21.2% | — | 2222.2% | |
Competitors are the stored peer set for KLRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 0 |
| Gross Profit | 0 |
| Gross Margin | — |
| Research & Development | 109.11M |
| Selling, General & Admin | 49.23M |
| Operating Expenses | 158.34M |
| Depreciation & Amortization | 310K |
| EBITDA | (158.03M) |
| EBITDA Margin | — |
| Operating Income | (158.34M) |
| Operating Margin | — |
| Interest Income | 11.05M |
| Interest Expense | 0 |
| Other Income / Expenses | 9.39M |
| Income Before Tax | (148.96M) |
| Pre-Tax Margin | — |
| Income Tax Expense | 0 |
| Net Income | (148.96M) |
| Net Margin | — |
| EPS (Basic) | (1.26) |
| EPS (Diluted) | (1.26) |
| Weighted Avg Shares | 117.95M |
| Weighted Avg Shares (Diluted) | 117.95M |
Kailera Therapeutics, Inc.
NASDAQ:KLRA
Intrinsic Alpha fair value
Locked
Current Price
$11.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.